- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly to spend $140M on new insulin cartridge plant
November 1, 2012
J.K. WallAbout 100 workers will staff the new plant, which will be constructed by spring 2014 and ready for operations in 2015. But
only “some” of that number will be new hires.
MoreSimon says Sandy caused minimal damage to shopping centers
October 30, 2012
Bloomberg NewsA company spokesman said damage was minor at Simon’s malls and outlet centers in New York and other areas hit by the
storm.
MoreLilly plans expansion of local insulin plant
October 30, 2012
J.K. WallThe Indianapolis-based drugmaker plans to expand its local insulin plants to make insulin cartridges to meet what it describes
as growing demand in the United States.
MoreLilly's Cialis receives European approval for new use
October 30, 2012
Associated PressThe European Union has approved Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied to an enlarged
prostate.
MoreLilly's insulin dip concerns analysts
October 29, 2012
J.K. WallEli Lilly and Co. suffered a tough week on the stock market, in part because of a disturbing bit of news buried in its third-quarter
earnings report: Lilly’s insulin sales are down.
MoreLilly misses analyst estimates, lowers profit forecast
October 24, 2012
J.K. WallThird-quarter earnings at Eli Lilly and Co. fell short of analysts' expectations, and the Indianapolis-based drugmaker reduced
its profit forecast by 4 cents per share for the remainder of the year.
MoreLilly CEO calls for life sciences research institute
October 23, 2012
J.K. WallEli Lilly CEO John Lechleiter on Tuesday called for creation of a "world-class" research institute in Indianapolis to bring
together scientists from universities and corporations to develop new medical therapies and companies.
MoreLilly continues string of positive trials
October 22, 2012
J.K. WallEli Lilly and Co. is continuing a string of positive yet incomplete clinical trial results, giving it a boost among investors.
MoreLilly says experimental diabetes drug outperformed rivals
October 22, 2012
J.K. WallEli Lilly and Co. said dulaglutide lowered blood sugar better than three existing diabetes drugs in three Phase 3 clinical
trials. Analysts expect the drug to hit the market in 2014 or 2015 and become a blockbuster.
MoreAlzheimer’s prevention seen promising as drug cures fail
October 19, 2012
Bloomberg NewsResearchers are set to test drugs by Eli Lilly and other companies that may prevent Alzheimer’s disease after efforts
to find a cure have been unsuccessful.
MoreLilly stomach-cancer drug helps survival, study finds
October 15, 2012
Bloomberg NewsEli Lilly and Co. shares rose nearly 5 percent Monday morning after it said a study found that its experimental stomach-cancer
drug helped patients with advanced disease live longer.
MoreLilly, Roche drugs chosen for Alzheimer’s prevention trial
October 10, 2012
Bloomberg NewsEli Lilly & Co.’s solanezumab and Roche Holding AG’s gantenerumab were selected for a long-term Alzheimer’s
trial run by Washington University at St. Louis scientists seeking to block the disease’s symptoms.
MoreLilly shares rise on Alzheimer's study results
October 8, 2012
J.K. WallEli Lilly and Co.’s Alzheimer’s drug slowed cognitive decline 34 percent in patients with mild forms of the disease,
according to an analysis of Lilly’s clinical trial data released Monday. Lilly’s share price jumped more than
5 percent on the news.
MoreLilly counting on diabetes products to challenge larger rivals
October 8, 2012
Bloomberg NewsEli Lilly and Co. is betting on a “broad” range of diabetes products including pills, insulins and a once-a-week
treatment to take on bigger competitors, said Enrique Conterno, president of Lilly Diabetes.
MoreState drug fraud cases on the rise, study says
September 27, 2012
Associated PressFederal and state prosecutors have collected more than $30 billion from drug companies for alleged fraud and illegal marketing
over the last 20 years, according to a new report by consumer advocacy group Public Citizen.
MoreGroup aims to cut costs of late-stage drugs
September 24, 2012
J.K. WallYou know things are bad in the fiercely competitive pharma industry when drugmakers start turning to each other for help.
But that’s exactly what happened last week when 10 major drug companies—including Eli Lilly and Co.—joined forces to cut costs
out of clinical trials.
MoreLilly competitor Novo investing $100M in China
September 24, 2012
Bloomberg NewsNovo Nordisk A/S, the world’s largest insulin maker, plans to spend $100 million on research in China. The move follows
a similar one by Indianapolis-based Eli Lilly, which opened a 150-person research center in Shanghai in May.
MoreLilly's Cialis gets European endorsement for new use
September 21, 2012
Associated PressA European committee has endorsed the use of Eli Lilly and Co.'s erectile dysfunction drug Cialis to treat symptoms tied
to an enlarged prostate.
MoreTen drugmakers team up to improve testing process
September 19, 2012
Associated PressPharmaceutical industry heavyweights, including Eli Lilly and Co., are teaming up to improve the way experimental drugs are
tested so they can get approved, and reach patients, faster.
MoreFDA drug-review deal may unravel as fiscal cliff looms
September 10, 2012
Bloomberg NewsA $6.4 billion accord for U.S. drug and medical-device reviews is set to unravel just three months after taking effect as
lawmakers squabble over budget cutbacks.
MoreEli Lilly aims to ramp up social media presence
September 8, 2012
J.K. WallThe drugmaker recently drafted social media guidelines it hopes can help it expand its use of social media to more of its
employees—without running afoul of regulators.
MoreLilly’s Alimta fails to extend survival in lung cancer study
September 6, 2012
Bloomberg NewsEli Lilly and Co. said Thursday that its cancer drug Alimta didn’t extend overall survival when combined with Roche
Holding AG’s Avastin in patients with a form of lung tumor.
MoreTwo more clinical trials go against Lilly
September 4, 2012
J.K. WallIn the midst of Eli Lilly and Co.’s surprisingly positive news about its experimental Alzheimer’s drug, the company
suffered two other setbacks with former stars of its pipeline.
MoreEli Lilly's top lawyer to retire at end of year
August 31, 2012
Associated PressIndianapolis-based drugmaker Eli Lilly and Co. said Thursday its general counsel, Robert Armitage, will retire at the end
of the year and be replaced by deputy general counsel Michael Harrington.
MoreLilly stops testing of experimental schizophrenia drug
August 29, 2012
Bloomberg NewsEli Lilly and Co. halted testing on an experimental treatment for schizophrenia after the company determined the drug was
unlikely to show a benefit in patients.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Sounds like angie's list could have benefitted from some sort of internet based service that rates various providers of services...anybody know of any?
These are the same CEO's who complain about working-class people who unionize and negotiate decent pay and benefits for the people who make businesses run.
Are millions in Angie's List advertising expenses going into CEO Bill Oesterle pocket also? http://advanceindiana.blogspot.com/2013/05/ibj-exposes-self-dealing-by-angies-list.html?utm_source=twitterfeed&utm_medium=twitter
This is actually worse than is being reported. The properties were gifted to Oesterle with more than $4.6 million dollars in taxpayer money. So not only is he screwing his shareholders with inflated sale prices, but he is double dipping considering Mayor Ballard gifted him all the money to buy the property. Guess being politically connected (Campaign chairman to Mitch Daniels) gives you a license to steal and a get out of jail free pass. http://www.ibj.com/city-will-give-angies-list-46-million-for-real-estate/PARAMS/article/28944
A non-compete clause is expected to keep Buchman from appearing on-air at WTHR for a year from the WISH contract’s expiration.